The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Anticancer Therapeutic Strategies Targeting p53 Aggregation
Abstract
p53 is a tumor suppressor protein that is mutated in more than 50% of cancer cases. When mutated, it frequently results in p53 oncogenic gain of function (GOF), resulting in a greater tendency to aggregate in the phase separation and phase transition pathway. GOFs related to p53 aggregation include chemoresistance, which makes therapy even more difficult. The therapies available for the treatment of cancer are still quite limited, so the study of new molecules and therapeutic targets focusing on p53 aggregates is a promising strategy against cancer. In this review, we classify anticancer molecules with antiaggregation properties into four categories: thiol alkylating agents, designed peptides, agents with chaperone-based mechanisms that inhibit p53 aggregation, and miscellaneous compounds with anti-protein aggregation properties that have been studied in neurodegenerative diseases. Furthermore, we highlight autophagy as a possible degradation pathway for aggregated p53. Here, considering cancer as a protein aggregation disease, we review strategies that have been used to disrupt p53 aggregates, leading to cancer regression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“amyloid proteins can increase the invasiveness of cancers.154”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 2×
“Mutp53 leads to LOFs, in addition to DN effects and GOFs, as previously mentioned.”
BackgroundPetitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Unfolding the role of protein misfolding in neurodegenerative diseases
Soto, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1007 · Cited by 1,506
Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
Soto, C., & Pritzkow, S. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0235-9 · Cited by 1,180
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes
Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406
Research works printed but not linked: 134
- Kern, 1992, Definition of a Consensus Binding Site for P53, Nat. Genet., 1, 45, 10.1038/ng0492-45 · DOI · Paper page
- Lane, 1992, P53, Guardian of the Genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
- Hupp, 1999, Regulation of P53 Protein Function through Alterations in Protein-Folding Pathways, Cell. Mol. Life Sci., 55, 88, 10.1007/s000180050272 · DOI
- Baugh, 2018, Why Are There Hotspot Mutations in the TP53 Gene in Human Cancers?, Cell Death Differ., 25, 154, 10.1038/cdd.2017.180 · DOI · Paper page
- Bullock, 2000, Quantitative Analysis of Residual Folding and DNA Binding in Mutant P53 Core Domain: Definition of Mutant States for Rescue in Cancer Therapy, Oncogene, 19, 1245, 10.1038/sj.onc.1203434 · DOI · Paper page
- Joerger, 2006, Structural Basis for Understanding Oncogenic P53 Mutations and Designing Rescue Drugs, Proc. Natl. Acad. Sci. USA, 103, 15056, 10.1073/pnas.0607286103 · DOI · Paper page
- Flores, 2002, Targeted Point Mutations of P53 Lead to Dominant-Negative Inhibition of Wild-Type P53 Function, Proc. Natl. Acad. Sci. USA, 99, 2948, 10.1073/pnas.052713099 · DOI · Paper page
- Prives, 2012, Mutant P53: One Name, Many Proteins, Genes Dev., 26, 1268, 10.1101/gad.190678.112 · DOI · Paper page
- 2021, Mutant P53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches, Front. Cell Dev. Biol., 8, 607670, 10.3389/fcell.2020.607670 · DOI · Paper page
- Stein, Y., Rotter, V., and Aloni-Grinstein, R. (2019). Gain-of-Function Mutant P53: All the Roads Lead to Tumorigenesis. Int. J. Mol. Sci., 20. · DOI · Paper page
- Ishimaru, 2003, Fibrillar Aggregates of the Tumor Suppressor P53 Core Domain, Biochemistry, 42, 9022, 10.1021/bi034218k · DOI · Paper page
- Rotter, 1983, P53, a Transformation-Related Cellular-Encoded Protein, Can Be Used As a Biochemical Marker for the Detection of Primary Mouse Tumor Cells, Proc. Natl. Acad. Sci. USA, 80, 2613, 10.1073/pnas.80.9.2613 · DOI
- Moll, 1992, Two Distinct Mechanisms Alter P53 in Breast Cancer: Mutation and Nuclear Exclusion, Proc. Natl. Acad. Sci. USA, 89, 7262, 10.1073/pnas.89.15.7262 · DOI · Paper page
- Bullock, 1997, Thermodynamic Stability of Wild-Type and Mutant P53 Core Domain, Proc. Natl. Acad. Sci. USA, 94, 14338, 10.1073/pnas.94.26.14338 · DOI · Paper page
- Rangel, 2012, Mutant P53 Aggregates into Prion-like Amyloid Oligomers and Fibrils: Implications for Cancer, J. Biol. Chem., 287, 28152, 10.1074/jbc.M112.340638 · DOI · Paper page
- Clos, 2013, Dual Role of P53 Amyloid Formation in Cancer; Loss of Function and Gain of Toxicity, Biochem. Biophys. Res. Commun., 430, 963, 10.1016/j.bbrc.2012.11.130 · DOI
- Gogna, 2012, Chaperoning of Mutant P53 Protein by Wild-Type P53 Protein Causes Hypoxic Tumor Regression, J. Biol. Chem., 287, 2907, 10.1074/jbc.M111.317354 · DOI
- Levy, 2011, Co-Localization of Mutant P53 and Amyloid-like Protein Aggregates in Breast Tumors, Int. J. Biochem. Cell Biol., 43, 60, 10.1016/j.biocel.2010.10.017 · DOI · Paper page
- Xu, 2011, Gain of Function of Mutant P53 by Coaggregation with Multiple Tumor Suppressors, Nat. Chem. Biol., 7, 285, 10.1038/nchembio.546 · DOI · Paper page
- Rangel, 2014, The Aggregation of Mutant P53 Produces Prion-like Properties in Cancer, Prion, 8, 75, 10.4161/pri.27776 · DOI
- Silva, 2014, Prion-like Aggregation of Mutant P53 in Cancer, Trends Biochem. Sci., 39, 260, 10.1016/j.tibs.2014.04.001 · DOI · Paper page
- Hompes, 2017, Nuclear Inclusion Bodies of Mutant and Wild-Type P53 in Cancer: A Hallmark of P53 Inactivation and Proteostasis Remodelling by P53 Aggregation, J. Pathol., 242, 24, 10.1002/path.4872 · DOI
- Petronilho, 2021, Phase Separation of P53 Precedes Aggregation and Is Affected by Oncogenic Mutations and Ligands, Chem. Sci., 12, 7334, 10.1039/D1SC01739J · DOI
- Yang, 2021, Mesoscopic Protein-Rich Clusters Host the Nucleation of Mutant P53 Amyloid Fibrils, Proc. Natl. Acad. Sci. USA, 118, e2015618118, 10.1073/pnas.2015618118 · DOI
- Wawrzynow, 2018, Chaperoning the Guardian of the Genome. The Two-Faced Role of Molecular Chaperones in P53 Tumor Suppressor Action, Biochim. Biophys. Acta—Rev. Cancer, 1869, 161, 10.1016/j.bbcan.2017.12.004 · DOI
- Rangel, 2015, Misfolding, Aggregation, and Disordered Segments in c-Abl and P53 in Human Cancer, Front. Oncol., 5, 97
- Pedrote, 2020, Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant P53 Amyloid Oligomers, iScience, 23, 100820, 10.1016/j.isci.2020.100820 · DOI
- Forget, K.J., Tremblay, G., and Roucou, X. (2013). P53 Aggregates Penetrate Cells and Induce the Co-Aggregation of Intracellular P53. PLoS ONE, 8. · DOI
- Rangel, 2019, P53 Reactivation with Induction of Massive Apoptosis-1 (PRIMA-1) Inhibits Amyloid Aggregation of Mutant P53 in Cancer Cells, J. Biol. Chem., 294, 3670, 10.1074/jbc.RA118.004671 · DOI
- Baudino, 2015, Targeted Cancer Therapy: The Next Generation of Cancer Treatment, Curr. Drug Discov. Technol., 12, 3, 10.2174/1570163812666150602144310 · DOI · Paper page
- Liu, 2019, The Past, Present and Future of Potential Small-Molecule Drugs Targeting P53-MDM2/MDMX for Cancer Therapy, Eur. J. Med. Chem., 176, 92, 10.1016/j.ejmech.2019.05.018 · DOI
- Parrales, 2015, Targeting Oncogenic Mutant P53 for Cancer Therapy, Front. Oncol., 5, 288, 10.3389/fonc.2015.00288 · DOI · Paper page
- Gomes, A.S., Ramos, H., and Inga, A. (2021). Structural and Drug Targeting Insights on Mutant P53. Cancers, 13. · DOI
- Mizuno, 2010, Mutant P53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway, Cell, 148, 244
- Lamark, 2012, Aggrephagy: Selective Disposal of Protein Aggregates by Macroautophagy, Int. J. Cell Biol., 2012, 736905, 10.1155/2012/736905 · DOI · Paper page
- Soteras, 2015, P53 Protein Aggregation Promotes Platinum Resistance in Ovarian Cancer, Oncogene, 34, 3605, 10.1038/onc.2014.296 · DOI
- Jung, 2020, Autophagy as a Decisive Process for Cell Death, Exp. Mol. Med., 52, 921, 10.1038/s12276-020-0455-4 · DOI · Paper page
- Xu, 2021, Regulation of P53 Stability as a Therapeutic Strategy for Cancer, Biochem. Pharmacol., 185, 114407, 10.1016/j.bcp.2021.114407 · DOI
- Chin, 1992, Modulation of Activity of the Promoter of the Human MDR1 Gene by Ras and P53, Science, 255, 459, 10.1126/science.1346476 · DOI · Paper page
- Zastawny, 1993, The Core Promoter Region of the P-Glycoprotein Gene Is Sufficient to Confer Differential Responsiveness to Wild-Type and Mutant P53, Oncogene, 8, 1529
- Chan, 2004, Mutant P53 Expression Enhances Drug Resistance in a Hepatocellular Carcinoma Cell Line, Cancer Chemother. Pharmacol., 53, 519, 10.1007/s00280-004-0767-4 · DOI · Paper page
- Blandino, 1999, Mutant P53 Gain of Function: Differential Effects of Different P53 Mutants on Resistance of Cultured Cells to Chemotherapy, Oncogene, 18, 477, 10.1038/sj.onc.1202314 · DOI · Paper page
- Tsang, 2005, P53-R175H Mutant Gains New Function in Regulation of Doxorubicin-Induced Apoptosis, Int. J. Cancer, 114, 331, 10.1002/ijc.20818 · DOI
- Chee, 2013, Wild-Type and Mutant P53 Mediate Cisplatin Resistance through Interaction and Inhibition of Active Caspase-9, Cell Cycle, 12, 278, 10.4161/cc.23054 · DOI · Paper page
- Do, 2012, Mutant P53 Cooperates with ETS2 to Promote Etoposide Resistance, Genes Dev., 26, 830, 10.1101/gad.181685.111 · DOI · Paper page
- Xu, 2014, Unequal Prognostic Potentials of P53 Gain-of-Function Mutations in Human Cancers Associate with Drugmetabolizing Activity, Cell Death Dis., 5, e1108, 10.1038/cddis.2014.75 · DOI
- Zhang, 2017, Proteomic Identification of ERP29 as a Key Chemoresistant Factor Activated by the Aggregating P53 Mutant ARG282TRP, Oncogene, 36, 5473, 10.1038/onc.2017.152 · DOI
- Wang, 2013, Mutant TP53 Enhances the Resistance of Glioblastoma Cells to Temozolomide by Up-Regulating O6-Methylguanine DNA-Methyltransferase, Neurol. Sci., 34, 1421, 10.1007/s10072-012-1257-9 · DOI
- Barak, 1993, Mdm2 Expression Is Induced by Wild Type P53 Activity, EMBO J., 12, 461, 10.1002/j.1460-2075.1993.tb05678.x · DOI · Paper page
- Lee, 2010, Implication of Necrosis-Linked P53 Aggregation in Acquired Apoptotic Resistance to 5-FU in MCF-7 Multicellular Tumour Spheroids, Oncol. Rep., 24, 73
- Singh, 2021, Mechanisms of Temozolomide Resistance in Glioblastoma—A Comprehensive Review, Cancer Drug Resist., 4, 17
- Hu, 2021, Targeting Mutant P53 for Cancer Therapy: Direct and Indirect Strategies, J. Hematol. Oncol., 14, 157, 10.1186/s13045-021-01169-0 · DOI · Paper page
- Wang, 2017, Multisite Aggregation of P53 and Implications for Drug Rescue, Proc. Natl. Acad. Sci. USA, 114, E2634
- Kanapathipillai, M. (2018). Treating P53 Mutant Aggregation-Associated Cancer. Cancers, 10. · DOI · Paper page
- Bauer, 2016, 2-Sulfonylpyrimidines: Mild Alkylating Agents with Anticancer Activity toward P53-Compromised Cells, Proc. Natl. Acad. Sci. USA, 113, E5271, 10.1073/pnas.1610421113 · DOI
- Palanikumar, 2021, Protein Mimetic Amyloid Inhibitor Potently Abrogates Cancer-Associated Mutant P53 Aggregation and Restores Tumor Suppressor Function, Nat. Commun., 12, 3962, 10.1038/s41467-021-23985-1 · DOI · Paper page
- Neal, A., Lai, T., Singh, T., Rahseparian, N., Grogan, T., Elashoff, D., Scott, P., Pellegrini, M., and Memarzadeh, S. (2021). Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers. Cancers, 13. · DOI · Paper page
- Zhang, 2020, Therapeutic Potential of ReACp53 Targeting Mutant P53 Protein in CRPC, Prostate Cancer Prostatic Dis., 23, 160, 10.1038/s41391-019-0172-z · DOI · Paper page
- Miller, 2019, Bifunctional Ligand Design for Modulating Mutant P53 Aggregation in Cancer, Chem. Sci., 10, 10802, 10.1039/C9SC04151F · DOI · Paper page
- Bauer, 2019, A Structure-Guided Molecular Chaperone Approach for Restoring the Transcriptional Activity of the P53 Cancer Mutant Y220C, Future Med. Chem., 11, 2491, 10.4155/fmc-2019-0181 · DOI
- Chen, 2017, Inhibition of P53 Mutant Peptide Aggregation In Vitro by Cationic Osmolyte Acetylcholine Chloride, Protein Pept. Lett., 24, 353, 10.2174/0929866524666170123142858 · doi:10.2174/0929866524666170123142858
- Campos, 2018, Resveratrol Prevents P53 Aggregation in Vitro and in Breast Cancer Cells, Oncotarget, 9, 29112, 10.18632/oncotarget.25631 · DOI
- Chen, 2017, Polyarginine and Its Analogues Inhibit P53 Mutant Aggregation and Cancer Cell Proliferation in Vitro, Biochem. Biophys. Res. Commun., 489, 130, 10.1016/j.bbrc.2017.05.111 · DOI
- Zhang, 2018, Role of Thiol Reactivity for Targeting Mutant P53, Cell Chem. Biol., 25, 1219, 10.1016/j.chembiol.2018.06.013 · DOI
- Butturini, E., Butera, G., Pacchiana, R., de Prati, A.C., Mariotto, S., and Donadelli, M. (2021). Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant P53 Isoforms. Cells, 10. · DOI
- Kaar, 2010, Stabilization of Mutant P53 via Alkylation of Cysteines and Effects on DNA Binding, Protein Sci., 19, 2267, 10.1002/pro.507 · DOI · Paper page
- Hainaut, 1993, Redox Modulation of P53 Conformation and Sequence-Specific DNA Binding in Vitrol, Cancer Res., 53, 4469
- Sun, 2003, Formation of Disulfide Bond in P53 Correlates with Inhibition of DNA Binding and Tetramerization, Antioxid. Redox Signal., 5, 655, 10.1089/152308603770310338 · DOI
- Bykov, 2002, Mutant P53-Dependent Growth Suppression Distinguishes PRIMA-1 from Known Anticancer Drugs: A Statistical Analysis of Information in the National Cancer Institute Database, Carcinogenesis, 23, 2011, 10.1093/carcin/23.12.2011 · DOI · Paper page
- Li, 2015, PRIMA-1met (APR-246) Inhibits Growth of Colorectal Cancer Cells with Different P53 Status through Distinct Mechanisms, Oncotarget, 6, 36689, 10.18632/oncotarget.5385 · DOI
- Krayem, 2016, P53 Reactivation by PRIMA-1Met (APR-246) Sensitises V600E/KBRAF Melanoma to Vemurafenib, Eur. J. Cancer, 55, 98, 10.1016/j.ejca.2015.12.002 · DOI
- Piyawajanusorn, 2019, PRIMA-1MET Induces Cellular Senescence and Apoptotic Cell Death in Cholangiocarcinoma Cells, Cancer Genom. Proteom., 16, 543, 10.21873/cgp.20156 · DOI
- Bykov, 2005, Reactivation of Mutant P53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs, J. Biol. Chem., 280, 30384, 10.1074/jbc.M501664200 · DOI · Paper page
- Liang, 2007, Re-Activation of the P53 Pathway Inhibits in Vivo and in Vitro Growth of Hormone-Dependent Human Breast Cancer Cells, Int. J. Oncol., 31, 777
- Zache, 2008, PRIMA-1MET Inhibits Growth of Mouse Tumors Carrying Mutant P53, Cell. Oncol., 30, 411
- Shi, 2008, In Vitro and in Vivo Cytotoxic Effects of PRIMA-1 on Hepatocellular Carcinoma Cells Expressing Mutant P53ser249, Carcinogenesis, 29, 1428, 10.1093/carcin/bgm266 · DOI
- Zandi, 2011, PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant P53, Clin. Cancer Res., 17, 2830, 10.1158/1078-0432.CCR-10-3168 · DOI · Paper page
- Spicer, 2014, Selective Chemical Protein Modification, Nat. Commun., 5, 4740, 10.1038/ncomms5740 · DOI · Paper page
- Wassman, 2013, Computational Identification of a Transiently Open L1/S3 Pocket for Reactivation of Mutant P53, Nat. Commun., 4, 1407, 10.1038/ncomms2361 · DOI · Paper page
- Cino, 2016, Aggregation Tendencies in the P53 Family Are Modulated by Backbone Hydrogen Bonds, Sci. Rep., 6, 32535, 10.1038/srep32535 · DOI
- Ghosh, 2014, Investigating the Intrinsic Aggregation Potential of Evolutionarily Conserved Segments in P53, Biochemistry, 53, 5995, 10.1021/bi500825d · DOI
- Goldschmidt, 2010, Identifying the Amylome, Proteins Capable of Forming Amyloid-like Fibrils, Proc. Natl. Acad. Sci. USA, 107, 3487, 10.1073/pnas.0915166107 · DOI · Paper page
- Blagosklonny, 2001, Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death, JNCI J. Natl. Cancer Inst., 93, 239, 10.1093/jnci/93.3.239-a · doi:10.1093/jnci/93.3.239-a
- Saibil, 2013, Chaperone Machines for Protein Folding, Unfolding and Disaggregation, Nat. Rev. Mol. Cell Biol., 14, 630, 10.1038/nrm3658 · DOI · Paper page
- Blanden, 2020, Zinc Shapes the Folding Landscape of P53 and Establishes a Pathway for Reactivating Structurally Diverse Cancer Mutants, eLife, 9, e61487, 10.7554/eLife.61487 · DOI · Paper page
- Rosenzweig, 2002, Metallochaperones: Bind and Deliver, Chem. Biol., 9, 673, 10.1016/S1074-5521(02)00156-4 · DOI · Paper page
- Givol, 2012, P53 Reactivation The Link to Zinc, Cell Cycle, 11, 2581, 10.4161/cc.21020 · DOI
- Formigari, 2013, The Effect of Zinc and the Role of P53 in Copper-Induced Cellular Stress Responses, J. Appl. Toxicol., 33, 527, 10.1002/jat.2854 · DOI
- Butler, 2003, Structure, Function, and Aggregation of the Zinc-Free Form of the P53 DNA Binding Domain, Biochemistry, 42, 2396, 10.1021/bi026635n · DOI · Paper page
- Richard, 2000, Metalloregulation of the Tumor Suppressor Protein P53: Zinc Mediates the Renaturation of P53 after Exposure to Metal Chelators in Vitro and in Intact Cells, Oncogene, 19, 5227, 10.1038/sj.onc.1203907 · DOI · Paper page
- Yu, 2014, Small Molecule Restoration of Wildtype Structure and Function of Mutant P53 Using a Novel Zinc-Metallochaperone Based Mechanism, Oncotarget, 5, 8879, 10.18632/oncotarget.2432 · DOI · Paper page
- Wang, 2012, First-Order Rate-Determining Aggregation Mechanism of P53 and Its Implications, Proc. Natl. Acad. Sci. USA, 109, 13590, 10.1073/pnas.1211557109 · DOI · Paper page
- Blanden, 2015, Erratum: Synthetic Metallochaperone ZMC1 Rescues Mutant P53 Conformation by Transporting Zinc into Cells as an Ionophore, Mol. Pharmacol., 88, 1084, 10.1124/mol.115.097550err · doi:10.1124/mol.115.097550err
- Garufi, 2013, A Fluorescent Curcumin-Based Zn(II)-Complex Reactivates Mutant (R175H and R273H) P53 in Cancer Cells, J. Exp. Clin. Cancer Res., 32, 72, 10.1186/1756-9966-32-72 · DOI
- Hartl, 2011, Molecular Chaperones in Protein Folding and Proteostasis, Nature, 475, 324, 10.1038/nature10317 · DOI · Paper page
- Doyle, 2013, Protein Rescue from Aggregates by Powerful Molecular Chaperone Machines, Nat. Rev. Mol. Cell Biol., 14, 617, 10.1038/nrm3660 · DOI · Paper page
- Yu, 2012, Allele-Specific P53 Mutant Reactivation, Cancer Cell, 21, 614, 10.1016/j.ccr.2012.03.042 · DOI · Paper page
- Boeckler, 2008, Targeted Rescue of a Destabilized Mutant of P53 by Ar in Silico Screened Drug, Chemtracts, 21, 236
- Basse, 2010, Toward the Rational Design of P53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant, Chem. Biol., 17, 46, 10.1016/j.chembiol.2009.12.011 · DOI · Paper page
- Wilcken, 2012, Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant P53, J. Am. Chem. Soc., 134, 6810, 10.1021/ja301056a · DOI · Paper page
- Joerger, 2015, Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant P53, Structure, 23, 2246, 10.1016/j.str.2015.10.016 · DOI
- Bauer, 2016, Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of P53 Mutant Y220C Rescue Drugs, ACS Chem. Biol., 11, 2265, 10.1021/acschembio.6b00315 · DOI
- Baud, 2018, Aminobenzothiazole Derivatives Stabilize the Thermolabile P53 Cancer Mutant Y220C and Show Anticancer Activity in P53-Y220C Cell Lines, Eur. J. Med. Chem., 152, 101, 10.1016/j.ejmech.2018.04.035 · DOI
- Huang, 2021, DAXX Represents a New Type of Protein-Folding Enabler, Nature, 597, 132, 10.1038/s41586-021-03824-5 · DOI
- Ross, 2004, Protein Aggregation and Neurodegenerative Disease, Nat. Med., 10, S10, 10.1038/nm1066 · DOI · Paper page
- Goedert, 2015, Alzheimer’s and Parkinson’s Diseases: The Prion Concept in Relation to Assembled Aβ, Tau, and α-Synuclein, Science, 349, 61, 10.1126/science.1255555 · DOI · Paper page
- Bredesen, 2006, Cell Death in the Nervous System, Nature, 443, 796, 10.1038/nature05293 · DOI · Paper page
- Klabunde, 2000, Rational Design of Potent Human Transthyretin Amyloid Disease Inhibitors, Nat. Struct. Biol., 7, 312, 10.1038/74082 · DOI
- Evers, 2009, Elucidating the Mechanism of Lipid Membrane-Induced IAPP Fibrillogenesis and Its Inhibition by the Red Wine Compound Resveratrol: A Synchrotron X-ray Reflectivity Study, J. Am. Chem. Soc., 131, 9516, 10.1021/ja8097417 · DOI
- Feng, 2009, Resveratrol Inhibits Beta-Amyloid Oligomeric Cytotoxicity but Does Not Prevent Oligomer Formation, Neurotoxicology, 30, 986, 10.1016/j.neuro.2009.08.013 · DOI · Paper page
- Florio, 2015, Transthyretin Binding Heterogeneity and Antiamyloidogenic Activity of Natural Polyphenols and Their Metabolites, J. Biol. Chem., 290, 29769, 10.1074/jbc.M115.690172 · DOI
- Gautam, 2017, Polyphenols in Combination with β-Cyclodextrin Can Inhibit and Disaggregate α-Synuclein Amyloids under Cell Mimicking Conditions: A Promising Therapeutic Alternative, Biochim. Biophys. Acta—Proteins Proteom., 1865, 589, 10.1016/j.bbapap.2017.02.014 · DOI
- Kulikov, 2015, Amphiphilic Oligoamide α-Helix Peptidomimetics Inhibit Islet Amyloid Polypeptide Aggregation, Tetrahedron Lett., 56, 3670, 10.1016/j.tetlet.2015.02.132 · DOI
- Kumar, 2015, Islet Amyloid-Induced Cell Death and Bilayer Integrity Loss Share a Molecular Origin Targetable with Oligopyridylamide-Based α-Helical Mimetics, Chem. Biol., 22, 369, 10.1016/j.chembiol.2015.01.006 · DOI
- Kumar, 2017, α-Helix Mimetics as Modulators of Aβ Self-Assembly, J. Am. Chem. Soc., 139, 5744, 10.1021/jacs.6b09734 · DOI
- Kumar, 2018, Peptidomimetic-Based Multidomain Targeting Offers Critical Evaluation of Aβ Structure and Toxic Function, J. Am. Chem. Soc., 140, 6562, 10.1021/jacs.7b13401 · DOI
- Hyun, S., and Shin, D. (2021). Chemical-Mediated Targeted Protein Degradation in Neurodegenerative Diseases. Life, 11. · DOI
- Ji, 2022, The AUTOTAC Chemical Biology Platform for Targeted Protein Degradation via the Autophagy-Lysosome System, Nat. Commun., 13, 904, 10.1038/s41467-022-28520-4 · DOI · Paper page
- Alexandrova, 2015, Improving Survival by Exploiting Tumour Dependence on Stabilized Mutant P53 for Treatment, Nature, 523, 352, 10.1038/nature14430 · DOI · Paper page
- Masciarelli, 2014, Gain-of-Function Mutant P53 Downregulates MiR-223 Contributing to Chemoresistance of Cultured Tumor Cells, Oncogene, 33, 1601, 10.1038/onc.2013.106 · DOI · Paper page
- Shi, 2021, Mutant P53 as a Regulator and Target of Autophagy, Front. Oncol., 10, 607149, 10.3389/fonc.2020.607149 · DOI
- Thorburn, 2020, Autophagy in Cancer: Moving from Understanding Mechanism to Improving Therapy Responses in Patients, Cell Death Differ., 27, 843, 10.1038/s41418-019-0474-7 · DOI · Paper page
- Mizushima, 2020, Autophagy Assays for Biological Discovery and Therapeutic Development, Trends Biochem. Sci., 45, 1080, 10.1016/j.tibs.2020.07.006 · DOI · Paper page
- Xu, 2020, Molecular Regulation of Autophagy Machinery by MTOR-Dependent and -Independent Pathways, Ann. N. Y. Acad. Sci., 1467, 3, 10.1111/nyas.14305 · DOI · Paper page
- Luo, 2018, HMGB1 Represses the Anti-Cancer Activity of Sunitinib by Governing TP53 Autophagic Degradation via Its Nucleus-to-Cytoplasm Transport, Autophagy, 14, 2155, 10.1080/15548627.2018.1501134 · DOI
- Rodriguez, 2012, Dietary Downregulation of Mutant P53 Levels via Glucose Restriction: Mechanisms and Implications for Tumor Therapy, Cell Cycle, 11, 4436, 10.4161/cc.22778 · DOI
- Yao, 2010, The Role of Ubiquitin in Autophagy-Dependent Protein Aggregate Processing, Genes Cancer, 1, 779, 10.1177/1947601910383277 · DOI
- Pankiv, 2007, P62/SQSTM1 Binds Directly to Atg8/LC3 to Facilitate Degradation of Ubiquitinated Protein Aggregates by Autophagy, J. Biol. Chem., 282, 24131, 10.1074/jbc.M702824200 · DOI · Paper page
- Gubas, 2022, A Guide to the Regulation of Selective Autophagy Receptors, FEBS J., 289, 75, 10.1111/febs.15824 · DOI · Paper page
- Ma, 2022, CCT2 Is an Aggrephagy Receptor for Clearance of Solid Protein Aggregates, Cell, 185, 1325, 10.1016/j.cell.2022.03.005 · DOI · Paper page
- Biel, 2020, Mitochondrial Dysfunction Generates Aggregates That Resist Lysosomal Degradation in Human Breast Cancer Cells, Cell Death Dis., 11, 460, 10.1038/s41419-020-2658-y · DOI
- Maan, 2018, CHIP Promotes Autophagy-Mediated Degradation of Aggregating Mutant P53 in Hypoxic Conditions, FEBS J., 285, 3197, 10.1111/febs.14602 · DOI
- Haque, 2018, Blocking Mutation Independent P53 Aggregation by Emodin Modulates Autophagic Cell Death Pathway in Lung Cancer, Int. J. Biochem. Cell Biol., 96, 90, 10.1016/j.biocel.2018.01.014 · DOI
- Choudhury, 2013, Dissecting the Pathways That Destabilize Mutant P53: The Proteasome or Autophagy?, Cell Cycle, 12, 1022, 10.4161/cc.24128 · DOI · Paper page
Cited by
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Ferretti, G. D. S., Quarti, J., dos Santos, G., Rangel, L. P., & Silva, J. L.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-09-20
- Volume
- 23
- Issue
- 19
- Pages
- 11023
- ISSN
- 1422-0067
- Cited by
- 24
- References
- 20
- Language
- en
- Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (465395/2014-7, 408046/2021-0, 210008/2018, 202840/2018, 88887-136390/2017)
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) (465395/2014-7, 408046/2021-0, 210008/2018, 202840/2018, 88887-136390/2017)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) (465395/2014-7, 408046/2021-0, 210008/2018, 202840/2018, 88887-136390/2017)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anticancer Therapeutic Strategies Targeting p53 Aggregation. https://app.cochat.ai/papers/10.3390/ijms231911023
- The paper
- Ferretti, G. D. S., Quarti, J., dos Santos, G., Rangel, L. P., & Silva, J. L. (2022). Anticancer Therapeutic Strategies Targeting p53 Aggregation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms231911023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.